AbbVie's Fast Becoming a Top Stock to Buy Now
AbbVie Inc.'s (NYSE: ABBV) making considerable progress toward reducing its reliance on its top-selling autoimmune disease drug, Humira, and recent patent news that could sideline Humira knock-offs beyond 2020 suggests that investors ought to take a good, hard look at owning this company's stock in their portfolio.
As of the second quarter, Humira generates about two-thirds of AbbVie's $28 billion in annualized sales. Clearly, sidestepping the threat posed by expiring Humira patents won't be easy.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Johnson & Johnson Stock
€136.02
-0.160%
With 34 Buy predictions and 1 Sell predictions Johnson & Johnson is one of the favorites of our community.
As a result the target price of 187 € shows a positive potential of 37.48% compared to the current price of 136.02 € for Johnson & Johnson.
